Boston Scientific (NYSE:BSX) enrolled the 1st patient in a new trial of its Lotus transcatheter aortic valve system, expecting to use the results to support a bid for European CE Mark and other international regulatory approvals.
The new study, Reprise II, will ultimately involve up to 120 patients at 15 centers in Australia, France, Germany and the U.K, according to a company statement.